Information Transfer. The Parties agree and acknowledge that Infinity has delivered to Novartis the information pursuant to Sections 2.2.4 and 3.3.3 of the Collaboration Agreement. From time to time during the term of this License Agreement, the Parties shall discuss any other information Controlled by Infinity that is necessary or useful for further development, manufacture and commercial exploitation and distribution of an Optioned Lead Program, Optioned Lead Program Compounds or Licensed Drug Product and Infinity shall promptly thereafter deliver such information to Novartis. This information shall also include copies of all Patents filed by Infinity pursuant to Section 2.3.2(h) of the Collaboration Agreement.
Appears in 4 contracts
Samples: Collaboration and Option Agreement, Collaboration and Option Agreement (Discovery Partners International Inc), Collaboration and Option Agreement (Infinity Pharmaceuticals, Inc.)
